Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
Mark Elliott Boulding Sells 3,019 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
04:44am, Wednesday, 25'th Feb 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Elliott Boulding sold 3,019 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average
PTC Therapeutics to Participate at Upcoming Investor Conferences
08:00am, Monday, 23'rd Feb 2026
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conferen
PTC Therapeutics: Sephience As A Major Growth Driver
07:26am, Monday, 23'rd Feb 2026
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Hun
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells $172,290.24 in Stock
06:24am, Monday, 23'rd Feb 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) EVP Lee Scott Golden sold 2,484 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at
PTC Therapeutics (NASDAQ:PTCT) CAO Sells $172,983.84 in Stock
06:24am, Monday, 23'rd Feb 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CAO Christine Marie Utter sold 2,494 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an
Matthew Klein Sells 7,371 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
05:37am, Sunday, 22'nd Feb 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CEO Matthew Klein sold 7,371 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at
19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB
04:58am, Sunday, 22'nd Feb 2026
Brummer Multi Strategy AB purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) during the third quarter, according to the company in its most recent 13F filing with the SEC. The in
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
01:24pm, Friday, 20'th Feb 2026
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
08:31pm, Thursday, 19'th Feb 2026
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Str
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
08:01pm, Thursday, 19'th Feb 2026
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Thursday, 19'th Feb 2026
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $11
Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:15am, Monday, 16'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared durin
PTC Therapeutics Provides Regulatory Update on Translarna™
05:00pm, Thursday, 12'th Feb 2026
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for th
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Thursday, 12'th Feb 2026
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
08:00am, Thursday, 05'th Feb 2026
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 f
